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The Journal of Molecular Diagnostics has developed a formal 
Scientific Integrity Policy in an effort to define more clearly issues 
of scientific misconduct in journal publishing. This document 
defines the common issues relating to appropriate scientific conduct 
as well as the procedures that will be followed should misconduct 
issues arise. In addition the Instructions to Authors 
(http://jmd.amjpathol.org/authorinfo) and Instructions to Reviewers 
(http://jmd.amjpathol.org/content/forReviewers) have been updated 
to reflect these changes.  
The policy is based on recommendations from the Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals 
(http://www.icmje.org), the CSE White Paper on Promoting 
Integrity in Scientific Journal Publications 
(http://www.councilscienceeditors.org/editorial_policies/white_pap
er.cfm), and the US Department of Health and Human Services’ 
Office of Research Integrity (http://ori.dhhs.gov). It should be noted 
that willful misconduct does not include incidents of honest 
misjudgment or inadvertent error. Any questions regarding the 
official policy of the Journal should be directed to the Editorial 
Office at 301-634-7959 or jmd@asip.org. 
Author Conduct 
General Authorship Guidelines. Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals 
(http://www.icmje.org) defines authorship as “1) substantial 
contributions to conception and design, or acquisition of data, or 
analysis and interpretation of data; 2) drafting the manuscript or 
revising it critically for important intellectual content; and 3) final 
approval of the version to be published. Authors should meet 
conditions 1, 2, and 3.” When work has been performed by a large, 
multi-center group, the group should designate individuals who 
accept direct responsibility for the manuscript on behalf of the group. 
These individuals should fully meet the criteria above and should 
disclose conflicts of interest (see below) on behalf of the group. All 
members of the group who meet authorship criteria should be 
provided for listing as a footnote.  
When submitting a manuscript to the Journal, the corresponding 
author takes responsibility on behalf of all authors for the authorship, 
authenticity and integrity of the research being reported. The email 
contact information of ALL authors is required so the Journal may 
formally contact the authors regarding any aspect of manuscript 
submission. If an author is removed during the course of revision of 
the manuscript, written explanation and consent by the removed 
author (signed letter or personal email) should be provided. Any 
change made to the list of authors (addition, removal, change in 
order) after manuscript acceptance requires consent of all authors 
and editorial approval. Authorship disputes are to be resolved by the 
authors and/or their institutions, not by the Journal. 
Because inclusion in the Acknowledgments may give the 
appearance of endorsement of the manuscript and its findings, 
authors should obtain permission from all individuals named in the 
Acknowledgments who contributed substantially to the work 
reported (eg, data collection, analysis, or writing/editing assistance) 
but did not fulfill the authorship criteria. Likewise, authors should 
receive permission from all individuals named as sources for 
personal communication or unpublished data. Such permissions 
should be affirmed by the corresponding author in the cover letter.  
Ghostwriting. As stated above, all persons contributing to the paper 
but not meeting authorship criteria should be listed in the 
Acknowledgments section. Further, any funding for writing support 
should be fully disclosed. If an outside source funded the assistance, 
the authors of the paper should also affirm that they are solely, and 
independently, responsible for the interpretation of the data and that 
they had full and open access to all of the data. It is considered 
unethical for any entity (eg, governmental, private, or commercial) 
with direct financial or personal interests to restrict the use of data 
or their interpretation for the sole purpose of presenting data in a 
manner that is favorable to its own interests or those of its affiliates. 
It is also unethical for any entity to be responsible for data gathering, 
interpretation, and/or presentation and then to solicit outside 
"authors" for the paper, as a means of hiding its relationship with 
the data.  
Peer Review Process. The Journal takes great care to secure the 
confidentiality and integrity of the peer-review process. It is the 
practice of the Journal to conduct a blinded peer-review process. 
Thus, it is considered a violation of this process for authors to 
identify or attempt to communicate directly with peer reviewers or 
Associate Editors regarding their manuscript. All editorial 
communications should be directed through the Editorial Office at 
jmd@asip.org. The Editors will consider any deliberate ethical 
violation in either the reported research or the manuscript 
preparation and review to be actionable misconduct, the potential 
results of which may be manuscript rejection or public article 
retraction, reporting of conduct to the authors’ governing 
institutions, and/or the denial to consider any future submissions to 
the Journal.  
Authors may request that specific reviewers not be used due to prior 
collaborations, known conflicts of interest, or direct competition. 
The Editors will make every effort to respect requests that are well-
founded; however, the Editors do have the authority to utilize such a 
reviewer if it is necessary for expert peer review.   
To aid the review process, authors should be ready to comply with 
Editors’ requests for copies of any similar works in preparation, 
copies of cited manuscripts that are submitted or in press, and/or 
supporting manuscript data (eg, data not shown but summarized in 
the manuscript). Failure to do so may result in rejection of the 
manuscript without further review.  
Financial Disclosure and Conflicts of Interest. All authors must 
disclose any current or former relationships (eg, employment, 
consultancies, board membership, stock ownership, funding, 
honoraria, expert testimony, patents or royalties, travel 
reimbursements, industry-supplied free reagents, etc.) with any 
organization or entity having a direct financial or personal interest in 
the subject matter or materials discussed in the manuscript. Authors 
should err on the side of full disclosure and should contact the 
Editorial Office if they have questions or concerns. This information 
should be provided at the time of submission (for new and revised 
manuscripts). All authors will be required to complete an online 
disclosure form following acceptance; details are provided in the 
acceptance letter. Failure to disclose conflicts of interest may result 
in manuscript rejection or editorial retraction of the article. 
Ethical Treatment of Research Subjects. If human subjects or 
samples were used, authors must affirm that the research protocol 
was approved by the appropriate institutional review boards or 
ethics committees for human (including use of human cells or 
tissues) experiments and that all human subjects provided 
appropriate informed consent. To protect patient privacy, 
identifying information such as names, initials, or hospital numbers 
should not be published unless the information is essential for 
scientific purposes and the patient (or parent/guardian) gives written 
informed consent for publication. If race/ethnicity is reported, 
authors should state who determined race/ethnicity, how the options 
were defined, and why race/ethnicity was important in the study. 
Authors should be prepared to provide study protocol number(s) if 
requested. 
Ethical Treatment of Animals. If animal experiments were 
performed, authors must affirm that the research protocol was 
approved by the appropriate institutional review boards or ethics 
 committees for animal experiments and that regulations concerning 
the use of animals in research were adhered to. Authors should be 
prepared to provide study protocol number(s) if requested. 
Copyright. Copyright of published manuscripts is held by the 
Association for Molecular Pathology and the American Society for 
Investigative Pathology, which must receive the assignment of 
copyright from the authors of accepted manuscripts. For US 
government employees, the above assignment applies only to the 
extent allowable by law. See 
http://www.asip.org/pubs/jmdrights.pdf for details. Requests to 
republish copyrighted materials, including the planned use, should 
be directed to the Editorial Office at 301-634-7959 or jmd@asip.org. 
Publishing in The Journal of Molecular Diagnostics automatically 
places authors in compliance with NIH Public Access Policy (see 
http://publicaccess.nih.gov/ submit_process.htm, Submission 
Method A). Any article noted as being funded by NIH, HHMI, 
Wellcome Trust, or MRC is deposited in PubMed Central (PMC), to 
be made available to the public twelve months after final print 
publication (unless the funding agency stipulates a sooner release 
date, such as six months). Authors therefore should NOT complete a 
separate deposit of their material but will be contacted by PubMed 
Central for grant verification once the article has been received by 
the PMC article system. For information on how to cite articles in 
NIH grant applications, please visit 
http://www.asip.org/pubs/AuthorNotice.cfm. 
Contact healthpermissions@elsevier.com regarding permission to 
deposit manuscripts in other government-sponsored repositories in 
cases where The Journal of Molecular Diagnostics does not have a 
system in place to automatically deposit materials on behalf of their 
authors. Deposit of accepted or published manuscripts in any non-
JMD repository without prior permission by the Journal is a 
violation of copyright. 
Embargo Policy. All information regarding the content of submitted 
or accepted manuscripts is strictly confidential. Information 
contained in or about accepted articles cannot appear in print, audio, 
video, or digital form or be released by the news media until the 
Journal embargo date has passed, not to exceed the publication date 
of the article. For detailed information on embargo release dates or 
for news media requests for preprint copies of specific articles, 
contact asipproduction@elsevier.com. 
Scientific Misconduct. According to the US Office of Research 
Integrity (http://ori.dhhs.gov), “fabrication is making up data or 
results and recording or reporting them; falsification is manipulating 
research materials, equipment, or processes, or changing or omitting 
data or results such that the research is not accurately represented in 
the research record; plagiarism is the appropriation of another 
person’s ideas, processes, results, or words without giving 
appropriate credit.” The Journal has a zero tolerance policy for such 
matters. For details regarding how the Journal handles such matters, 
see the later section on Allegations of Misconduct.  
Fabrication of Data. Any evidence of fraudulent methods, data, or 
data analysis may prompt the Editors to request an explanation and 
access to original data, which the authors must supply.  
Falsification of Data. The results presented in the manuscript must 
accurately represent the data obtained in the course of authors’ 
studies; omission of contradictory or negative data in an effort to 
support the main hypothesis is unacceptable. Taking photographs of 
the same source under varied fields of view, light intensity, 
magnifications, or contrast conditions without disclosing that the 
data are not unique to the present study constitutes suspect scientific 
conduct. Further, unless serial sections are used, the publication of 
identical-appearing images labeled with different staining 
techniques in different papers raises legitimate questions. No 
specific feature within an image may be enhanced, obscured, moved, 
removed, or introduced. The grouping of images from different 
parts of the same gel or blot, or from different gels or blots, fields, 
or exposures must be made explicit by the arrangement of the figure 
(eg, using dividing lines) and in the figure legend. Adjustments of 
brightness, contrast, or color balance are acceptable only if they are 
applied to the whole image, whether experimental or control image, 
and as long as they do not obscure or eliminate any information 
present in the original (Portions adapted with permission from the 
JCB). Any evidence of inappropriate manipulation may prompt the 
Editors to request an explanation and access to original data, which 
the authors must make available.  
Plagiarism. Authors should carefully note that the use of another 
person’s data or ideas without permission constitutes plagiarism. 
Authors may not republish copyrighted Journal material in whole or 
in part without the express permission of the copyright holder, the 
American Society for Investigative Pathology and the Association 
for Molecular Pathology. Likewise, copyrighted material previously 
published in another form may not be published in the Journal 
without express permission from the original copyright holder. 
These rules cover work previously written by the authors. Authors 
wishing to republish images, tables, or text should provide proof of 
such permission with their submission and should include the 
appropriate attribution in the figure or table legend or in the text.  
Redundant Publication. “Redundant (or duplicate) publication is 
publication of a paper that overlaps substantially with one already 
published in print or electronic media,” as defined by the Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals 
(http://www.icmje.org). Authors must certify upon submission that 
the manuscript has not been accepted or published elsewhere and 
that it is not currently under review at another journal. Likewise, 
manuscripts under consideration by the Journal should not be 
submitted or published elsewhere. Publication of short abstracts in 
meeting proceedings does not violate this standard. Submissions 
will be ineligible for review if previously published in any form 
(print or online) other than as an abstract. This includes any public 
posting of raw manuscripts or pre-reviewed material. If there is any 
doubt, the authors should contact the Editorial Office for guidance. 
Reviewer Conduct 
Peer Review Process. Reviewers are expected to take their 
obligation seriously and to consider carefully the merits of the 
manuscript being assessed. Any delays in completing a review 
should be brought to the immediate attention of the Editorial Office 
so that we may assess the situation and make adjustments as needed. 
It is the practice of The Journal of Molecular Diagnostics to 
conduct a blinded peer-review process; it is considered a violation 
of this process for peer reviewers to identify themselves or attempt 
to communicate directly with authors regarding the reviewed 
manuscript without the express permission of the Editors. All 
editorial communications should be directed through the Editorial 
Office at jmd@asip.org. The Editors will consider any deliberate 
ethical violation during peer review of a manuscript to be actionable 
misconduct, the potential results of which may be reporting of 
conduct to the Reviewer’s governing institution, dismissal as a peer 
reviewer for the Journal, and/or the denial to consider any future 
submissions to the Journal.  
Confidentiality. The manuscript is considered a privileged 
communication. When reviewing a manuscript for the Journal, the 
peer reviewer takes responsibility for maintaining its confidentiality. 
Reviewers should not retain copies of submitted manuscripts for 
personal use after completing their review. Reviewers are not 
allowed to make any use of the work described in the manuscript or 
take advantage of the knowledge gained by reviewing it until and 
unless it is published.  
If necessary, the manuscript may be discussed with a colleague in an 
effort to reach a decision. In such instances, the Reviewer must 
inform the colleague of the manuscript’s confidentiality and ask that 
they disclose any potential conflicts of interest. Information 
regarding additional assistance (colleague’s name and disclosure 
information as well as a description of the level of assistance) 
should be included in the “Confidential Comments to the Editor” 
portion of the online reviewer form. 
Financial Disclosure and Conflicts of Interest. Reviewers must 
disclose to the Editors any current or former relationships (eg, 
employment, consultancies, board membership, stock ownership, 
funding, honoraria, expert testimony, patents or royalties, travel 
reimbursements, etc.) with any organization or entity having a direct 
financial or personal interest in the subject matter or materials 
discussed in the manuscript that could bias their opinions of the 
manuscript. Reviewers should also consider potential conflicts of 
interest arising from personal relationships or academic competition. 
Personal relationships include family members, colleagues (such as 
collaborators, mentors, students, or trainees), or associates at a 
Reviewer’s institution. At least three years should elapse between 
the ending of such a relationship and participation in any review. 
However, for certain relationships such as student-mentor, three 
years may not be sufficient time, especially if both investigators 
continue to work in the same field. Thus, Reviewers must err on the 
side of caution and decline any assignments in which the suggestion 
of a conflict or bias could be raised. By agreeing to review a 
manuscript, Reviewers implicitly affirm that any potential conflicts 
of interest have been disclosed to the Editors and that they are able 
to provide an impartial review of the manuscript. 
Editor Conduct 
Peer Review Process. The Editor-in-Chief, Senior Associate Editor, 
and Associate Editors, are expected to take their obligation seriously 
and to maintain the highest standard of ethics during the peer-review 
process. Editors should perform their editorial duties without bias 
for or against any person or institution. Any delays in completing 
the disposition of a manuscript should be brought to the immediate 
attention of the Editorial Office so that the situation may be resolved. 
It is considered a violation for Editors to communicate directly with 
authors regarding their manuscript outside of normal editorial 
practices. It is also a violation for the Editors to reveal Reviewers’ 
names to authors without Reviewer consent; as the Journal conducts 
a blinded peer-review process, such revelations are extremely rare. 
Any deliberate ethical violation during peer review of a manuscript 
is considered to be actionable misconduct, the potential results of 
which may be reporting of conduct to the Editor’s governing 
institution, dismissal as an Editor for the Journal, and/or the denial 
to consider any future submissions to the Journal.  
Editors should respect author requests to exclude specific reviewers 
due to prior collaborations, known conflicts of interest, or direct 
competition when such requests are well-founded; however, Editors 
have the authority to utilize such a reviewer if they feel it is 
necessary for expert peer review. Such decisions should be made 
only after careful consideration and after other options have been 
exhausted 
Confidentiality. The Editors are subject to the same confidentiality 
requirements as Reviewers. Further, Editors must not disclose 
information about manuscripts (including their receipt, content, 
status in the reviewing process, Reviewers’ comments, or final 
disposition) to anyone other than the authors, Reviewers, and 
Journal staff. Editors should not retain copies of submitted 
manuscripts for personal use after completing their disposition. 
Editors are not allowed to make any use of the work described in the 
manuscript or take advantage of the knowledge gained by reviewing 
it until and unless it is published.  
Financial Disclosure and Conflicts of Interest. Editors must also 
carefully consider whether there exist any current or former 
relationships (eg, employment, consultancies, board membership, 
stock ownership, funding, honoraria, expert testimony, patents or 
royalties, travel reimbursements, etc.) with any organization or 
entity having a direct financial or personal interest in the subject 
matter or materials discussed in the manuscript that could bias their 
opinions of the manuscript. Editors should also consider potential 
conflicts of interest arising from personal relationships or academic 
competition. Personal relationships include family members, 
colleagues (such as collaborators, mentors, students, or trainees), or 
associates at the Editor’s institution. At least three years should 
elapse between the ending of such a relationship and participation in 
any review. However, for certain relationships such as student-
mentor, three years may not be sufficient time, especially if both 
investigators continue to work in the same field. Thus, Editors must 
err on the side of caution and decline any assignments in which the 
suggestion of a conflict or bias could be raised. By agreeing to 
review a manuscript, the Editor implicitly affirms that conflicts do 
not exist. In cases where the Editor-in-Chief has a conflict of 
interest, the Senior Associate Editor or another Associate Editor will 
handle the full disposition of the manuscript.   
Staff Conduct 
Peer Review Process. When handling a manuscript for the Journal, 
the Journal staff is expected to interact courteously and respectfully 
with authors, Reviewers, and Editors. They should not misrepresent 
the review process to authors or Reviewers. They should not forge, 
fabricate, or alter the scientific content of Reviewer comments. 
They should ensure timely disposition of reviewed manuscripts and 
publication of accepted manuscripts.  
Confidentiality. The Journal staff is subject to the same 
confidentiality standards as Editors. It is considered a violation of 
this confidentiality for staff to reveal Reviewer names or to 
communicate directly with authors regarding their manuscript 
outside of normal editorial practices.  
Allegations of Misconduct 
Reporting Suspected Misconduct. To maintain the integrity and 
high standards of the scientific publishing process, the Journal 
welcomes reporting of possible misconduct or other concerns 
related to manuscripts published or under review by the Journal. 
Suspected misconduct relating to authors, Reviewers, or Editors 
should be reported in writing to the Editorial Office at The Journal 
of Molecular Diagnostics, 9650 Rockville Pike, Bethesda, Maryland, 
USA 20814-3993 or jmd@asip.org. Issues relating to staff conduct 
should be directed to the ASIP Executive Officer (AMP Executive 
Officer Emeritus) at American Society for Investigative Pathology, 
9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or 
mesobel@asip.org. Willful misconduct does not include incidents of 
honest misjudgment or inadvertent error. 
The anonymity of the whistleblower(s) will be maintained 
throughout these procedures. With respect to all other 
communications arising from examination of misconduct, the ability 
to effectively investigate and administer an allegation of scientific 
misconduct shall be carefully balanced with the need to maintain 
confidentiality in order to protect the rights and reputations of all 
concerned. 
Procedures for Suspected Author Misconduct. Upon written 
notification of possible author misconduct, the Editors and Editorial 
Office will first perform a preliminary evaluation to determine if 
there is merit to the claims. The Editors reserve the right to involve 
the Joint Journal Oversight Committee, Executive Officers of AMP 
or ASIP, and/or legal counsel as deemed appropriate. If the 
manuscript is currently under review, the review process will be put 
on hold pending resolution. If the claims appear to have merit, the 
next step is to contact the authors.  
The Editor-in-Chief will contact the corresponding author and 
request a formal written response to the Editors’ concerns, and may 
ask to see source data, within 30 days. Authors are expected to 
cooperate fully and in good faith. Upon review of said explanation 
and data, the Editors and Editorial Office will determine whether an 
innocent error was committed (requiring publication of a Correction 
or Retraction) or whether further reporting or investigation is 
warranted. If needed, the authors’ institutions and/or funding 
agencies will be contacted, as it is not the responsibility of the 
Journal to perform such an investigation. During the investigation, 
the Journal will not receive or review new manuscripts from authors 
named in the disputed manuscript.  
The appropriate authorities at the authors’ institutions and/or 
funding agencies will be notified of the original complaint and may 
be asked to conduct an independent investigation. Once an 
investigation has begun, the Editors may choose to publish a Note of 
Concern informing the scientific community that an investigation is 
underway regarding the article in question. The investigation is 
expected to proceed in a timely manner, and upon completion of an 
investigation, the institution should quickly notify the Journal of its 
findings.  
If an institution or funding agency declines to conduct an 
investigation on a timely basis, or if an author does not have such an 
affiliation, the Journal may conduct its own investigation. 
If all authors are cleared of any wrongdoing, an unpublished 
manuscript may re-enter the review process. If a Note of Concern 
was published, the Journal will publish a Correction to rectify the 
matter in the public record. 
Upon receiving final determination of misconduct (including final 
appeal), the Journal may publish a Correction, Note of Concern, or 
 Retraction, depending on the findings of the investigation and the 
effect on the paper as a whole. If misconduct is determined by the 
authors’ institutions, then the Editors may request that the authors 
retract their paper. If the authors refuse, the Journal will notify all 
authors of the intent to publish a Retraction, to which the authors 
have 30 days to respond. The final Retraction will describe the 
reason for retraction as well as a list of authors agreeing (and if 
necessary those disagreeing) with the retraction. For unpublished 
manuscripts, the manuscript may be rejected or acceptance may be 
rescinded. Depending on the severity of the misconduct committed, 
the authors may be excluded from submitting new manuscripts for a 
period of time. 
At any point during the course of the investigation, the authors may 
withdrawal their unpublished manuscript or request a Retraction. If 
this occurs prior to formal investigation, the Editors may still 
determine to inform the authors’ institutions and/or funding 
agencies. 
These procedures do not supersede or diminish the general authority 
of the Journal to reject a manuscript as part of the review process. 
Procedures for Suspected Editorial Misconduct (Reviewers, 
Editors, Staff). Upon written notification of possible editorial 
misconduct, the Editors and/or Editorial Office will first perform a 
preliminary evaluation to determine if there is merit to the claims. If 
the complaint involves an Editor or Journal staff, that person will be 
excluded from any review. The Editors reserve the right to involve 
the Joint Journal Oversight Committee, Executive Officers of ASIP 
or AMP, and/or legal counsel as deemed appropriate. If the claims 
appear to have merit, the next step is to contact the person involved.  
The Editor-in-Chief or Executive Officer of ASIP or AMP will 
contact the person involved, requesting a formal response to the 
concerns within 30 days. Upon review of said explanation, the 
Editors and Editorial Office will determine whether an innocent 
error was committed or whether further investigation or reporting is 
warranted. If needed, the person’s institution and/or funding agency 
will be contacted, as it is not the responsibility of the Journal to 
perform such an investigation. During the investigation, the Editor 
or Reviewer will be excluded from reviewing or submitting new 
manuscripts.  
The appropriate authorities at the person’s institution will be 
notified of the original complaint and may be asked to conduct an 
independent investigation. The investigation is expected to proceed 
in a timely manner, and upon completion of an investigation, the 
institution should quickly notify the Journal of its findings.  
Upon receiving final determination of misconduct (including final 
appeal), the Journal may publish a Note of Concern if the 
disposition of a manuscript(s) was affected.   
Depending on the severity of the misconduct committed, the Editor, 
Reviewer, or Journal staff may be relieved of all future Journal-
related duties.  
These procedures do not supersede or diminish the general authority 
of the Journal to dismiss an Editor, Reviewer, or Journal staff. 
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